The latest report by IMARC Group, titled "Biopharmaceutical Manufacturing Market Report by Cell Culture (Mammalian Cell Culture, Microbial Cell Culture), Class (Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH)), and Region 2024-2032," finds that the global biopharmaceutical manufacturing market size reached US$ 411.8 Billion in 2023. Biopharmaceutical manufacturing refers to the process of producing pharmaceutical products, such as drugs and therapies, that are derived from biological sources. Unlike traditional pharmaceutical manufacturing, which involves chemical synthesis, biopharmaceutical manufacturing utilizes living organisms, cells, or their components to produce therapeutic substances. It involves various steps, including cell culture, fermentation, purification, and formulation, to produce biologically active molecules like proteins, antibodies, enzymes, or nucleic acids. The manufacturing process requires stringent quality control, adherence to Good Manufacturing Practices (GMP), and regulatory compliance to ensure safety, efficacy, and purity of biopharmaceutical products. Biopharmaceutical manufacturing plays a crucial role in providing innovative and effective treatments for various diseases, including cancer, autoimmune disorders, and genetic conditions.
Global Biopharmaceutical Manufacturing Market Trends:
One of the primary factors driving the market is the growing demand for biologic drugs, including monoclonal antibodies, vaccines, and recombinant proteins. Biologics offer targeted and personalized treatment options for various diseases, leading to an increase in the adoption of biopharmaceutical manufacturing. Additionally, the rising incidence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has fueled the demand for innovative and targeted therapies. Biopharmaceuticals have shown promising results in the treatment of these diseases, leading to rising investment in biopharmaceutical manufacturing to meet the growing market needs. Other than this, numerous biopharmaceutical companies are outsourcing their manufacturing activities to specialized contract manufacturing organizations (CMOs), as outsourcing allows companies to access specialized expertise, reduce costs, and focus on their core competencies. Besides this, advances in biotechnology, such as genetic engineering, cell culture technologies, and bioprocessing techniques, have significantly improved the production efficiency and scalability of biopharmaceuticals. These advancements have enabled the development of complex and highly effective biologic drugs, stimulating the growth of the biopharmaceutical manufacturing market. Furthermore, regulatory agencies have implemented supportive policies and guidelines to streamline the approval process for biological drugs. This has encouraged biopharmaceutical companies to invest in manufacturing infrastructure and expand their production capacities, thus impelling the market growth. Moreover, continuous improvements in manufacturing processes, such as single-use technologies, process automation, and advanced analytics, have enhanced productivity, efficiency, and cost-effectiveness in biopharmaceutical manufacturing. These advancements have contributed to the expansion of manufacturing capacities. On account of these factors, IMARC Group expects the market value to reach US$ 935.0 Billion by 2032, exhibiting a CAGR of 9.3% during the forecast period (2024-2032).
Market Summary:
- On the basis of the cell culture, the market has been segmented into mammalian and microbial. At present, mammalian cells represent the largest segment.
- Based on the class, the market has been categorized into monoclonal antibodies, recombinant proteins, interferon, granulocyte colony-stimulating factor (G-CSF), erythropoietin, recombinant human insulin, vaccines, and human growth hormones (HGH). Presently, monoclonal antibodies account for the majority of the market share.
- Region-wise, North America holds the leading position in the market. Other major regions include Asia and Europe.
- The competitive landscape of the market has been examined in the report, with some of the key players being AbbVie Inc., Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc. and Sanofi S.A.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
Kilo Liters |
Cell Cultures Covered |
Mammalian, Microbial |
Classes Covered |
Monoclonal Antibodies, Recombinant Proteins, Interferon, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoietin, Recombinant Human Insulin, Vaccines, Human Growth Hormones (HGH) |
Region Covered |
North America, Europe, Asia |
Companies Covered |
AbbVie Inc., Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc. and Sanofi S.A. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800